{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:41:45Z","timestamp":1792662105811,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40119-026-00479-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:03:20Z","timestamp":1791385400000},"page":"95-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-6587","authenticated-orcid":false,"given":"Nowell M.","family":"Fine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3321-7064","authenticated-orcid":false,"given":"Nicholas S.","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-9631","authenticated-orcid":false,"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-5066","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Agostinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":false,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8350-5351","authenticated-orcid":false,"given":"Martin","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Amass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-9475","authenticated-orcid":false,"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"8","key":"479_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010.","journal-title":"JACC Heart Fail"},{"issue":"22","key":"479_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"479_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. https:\/\/doi.org\/10.1186\/1750-1172-8-31.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"479_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","volume":"13","author":"J Gonzalez-Moreno","year":"2024","unstructured":"Gonzalez-Moreno J, Dispenzieri A, Grogan M, et al. Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. Cardiol Ther. 2024;13(1):117\u201335. https:\/\/doi.org\/10.1007\/s40119-023-00344-3.","journal-title":"Cardiol Ther"},{"issue":"1","key":"479_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cjco.2025.09.015","volume":"8","author":"P Arivalagan","year":"2026","unstructured":"Arivalagan P, Loza RC, Nugaeva N, et al. Detecting polyneuropathy in patients with hereditary transthyretin amyloid cardiomyopathy. CJC Open. 2026;8(1):9\u201315. https:\/\/doi.org\/10.1016\/j.cjco.2025.09.015.","journal-title":"CJC Open"},{"issue":"11","key":"479_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"2","key":"479_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40119-024-00362-9","volume":"13","author":"N Streicher","year":"2024","unstructured":"Streicher N, Amass L, Wang R, et al. Real-world effectiveness of high-dose tafamidis on neurologic disease progression in mixed-phenotype variant transthyretin amyloid cardiomyopathy. Cardiol Ther. 2024;13(2):359\u201368. https:\/\/doi.org\/10.1007\/s40119-024-00362-9.","journal-title":"Cardiol Ther"},{"key":"479_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-025-00421-9","author":"J Wixner","year":"2025","unstructured":"Wixner J, Dispenzieri A, Amass L, et al. Survival in a contemporary, real-world cohort of patients with mixed-phenotype transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from THAOS. Cardiol Ther. 2025. https:\/\/doi.org\/10.1007\/s40119-025-00421-9.","journal-title":"Cardiol Ther"},{"key":"479_CR9","unstructured":"Medical Research Council. Aids to the examination of the peripheral nervous system: memorandum No. 45. London; 1976."},{"issue":"6","key":"479_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jacc.2017.06.024","volume":"70","author":"J Afilalo","year":"2017","unstructured":"Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 2017;70(6):689\u2013700. https:\/\/doi.org\/10.1016\/j.jacc.2017.06.024.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"479_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675\u201382. https:\/\/doi.org\/10.1212\/WNL.0000000000001870.","journal-title":"Neurology"},{"issue":"1","key":"479_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02094-y","volume":"21","author":"X Lin","year":"2021","unstructured":"Lin X, Yarlas A, Vera-Llonch M, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurol. 2021;21(1):70. https:\/\/doi.org\/10.1186\/s12883-021-02094-y.","journal-title":"BMC Neurol"},{"issue":"2","key":"479_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83(2):152\u20138. https:\/\/doi.org\/10.1136\/jnnp-2011-301299.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"479_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024;9(1):25\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.4147.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"479_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","volume":"30","author":"R Rettl","year":"2023","unstructured":"Rettl R, Duca F, Binder C, et al. Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy. Amyloid. 2023;30(1):127\u201337. https:\/\/doi.org\/10.1080\/13506129.2022.2131385.","journal-title":"Amyloid"},{"key":"479_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.12.082","author":"B Ansari","year":"2026","unstructured":"Ansari B, Barrera NI, Bampatsias D, et al. Increase in serum transthyretin after tafamidis is associated with improved survival in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.12.082.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"479_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/13506129.2021.1904390","volume":"28","author":"SE Saith","year":"2021","unstructured":"Saith SE, Gamino D, Teruya S, et al. Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. Amyloid. 2021;28(4):267\u20138. https:\/\/doi.org\/10.1080\/13506129.2021.1904390.","journal-title":"Amyloid"},{"issue":"4","key":"479_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","volume":"3","author":"RH Falk","year":"2021","unstructured":"Falk RH, Haddad M, Walker CR, Dorbala S, Cuddy SAM. Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2021;3(4):580\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2021.08.007.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"479_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40119-026-00472-6","volume":"15","author":"N Streicher","year":"2026","unstructured":"Streicher N, Wubet H. Polyneuropathy assessment and treatment patterns in patients with hereditary transthyretin amyloidosis. Cardiol Ther. 2026;15(3):365\u201375. https:\/\/doi.org\/10.1007\/s40119-026-00472-6.","journal-title":"Cardiol Ther"},{"issue":"5","key":"479_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00479-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:15:35Z","timestamp":1792660535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00479-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00479-z","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nowell Fine: Research support and consulting honoraria from Pfizer, Alnylam, Eidos\/BridgeBio, AstraZeneca, Ionis, NovoNordisk, Janssen, and Sanofi. Nicholas S. Streicher: Investigator (at the time of the research) affiliated with MedStar Health\/Georgetown University School of Medicine, which received funding from Pfizer to support the research. Isabel Concei\u00e7\u00e3o: Research support and consultancy from Pfizer, Alnylam, Ionis Pharmaceuticals, Inc., and AstraZeneca. Jo\u00e3o Agostinho: Consultancy and speaker fees from Alnylam, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Menarini, Pfizer and Prothena. Laura Obici: Speaker honoraria from Alnylam, AstraZeneca, Bayer, BridgeBio, Novo Nordisk, Intellia, Medison, and Pfizer; and consulting fees from Alnylam, AstraZeneca, Bayer, BridgeBio, Novo Nordisk, Intellia, Purpose Pharma, and Pfizer. Giovanni Palladini: Advisory Board with AbbVie, Alexion, Attralus, Bayer, GSK, Life Molecular Science, Protego, Pfizer, Prothena, and Regeneron; and honoraria from The Binding Site. Martin Carlsson: Employment and stock\/stock options with Pfizer. Leslie Amass: Employment and stock\/stock options with Pfizer. Farooq H. Sheikh: Investigator affiliated with MedStar Health\/Georgetown University School of Medicine, which received funding from Pfizer to support the research; research support from Abbott, Alnylam, AstraZeneca, BridgeBio, Intellia; and consultant for Abbott, Alnylam, Astra Zeneca, BridgeBio, CVRx, Pfizer, Procyrion, and XVIVO.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study utilized anonymized structured data that contained no personal patient information. The protocol was approved by the institutional review board or ethics committee at each participating site (Canada: The Conjoint Health Research Ethics Board (CHREB), University of Calgary [approval number: REB24-1509]; Italy: Fondazione IRCCS Policlinico San Matteo, Comitato Etico Territoriale Lombardia 6 [0032861\/25]; Portugal: Unidade Local de Saude Santa Maria, Comissao de Etica do CAML [309\/24]; US: Medstar Health Research Institute Institutional Review Board [STUDY00007819]). Requirements for informed consent were determined according to local country regulations; patients in Portugal and Italy provided informed consent, whereas the informed consent requirement was waived in the United States and Canada. The study was conducted in accordance with applicable legal and regulatory requirements, following generally accepted research practices as outlined in the Guidelines for Good Pharmacoepidemiology Practices (GPP) and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}